Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.64 |
| ▸ | NOD2 | Q9HC29 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | THRB | P10828 | 1/20 | 0.40 |
| ▸ | LGALS8 | O00214 | 2/20 | 0.37 |
| ▸ | PYGB | P11216 | 1/20 | 0.36 |
| ▸ | KDR | P35968 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL33302 | 1.00 | MAPK1 (0.64) | MAPK1NOD2ALDH1A1THRBLGALS8 | |
| SCHEMBL30987364 | 1.00 | MAPK1 (0.64) | MAPK1NOD2ALDH1A1THRBLGALS8 | |
| SCHEMBL42791 | 1.00 | MAPK1 (0.64) | MAPK1NOD2ALDH1A1THRBLGALS8 | |
| SCHEMBL2728425 | 1.00 | MAPK1 (0.64) | MAPK1NOD2ALDH1A1THRBLGALS8 | |
| SCHEMBL16241534 | 1.00 | MAPK1 (0.64) | MAPK1NOD2ALDH1A1THRBLGALS8 | |
| SCHEMBL42792 | 1.00 | MAPK1 (0.64) | MAPK1NOD2ALDH1A1THRBLGALS8 | |
| SCHEMBL17184967 | 1.00 | MAPK1 (0.64) | MAPK1NOD2ALDH1A1THRBLGALS8 | |
| SCHEMBL20533512 | 1.00 | MAPK1 (0.64) | MAPK1NOD2ALDH1A1THRBLGALS8 | |
| SCHEMBL22163862 | 1.00 | MAPK1 (0.64) | MAPK1NOD2ALDH1A1THRBLGALS8 | |
| Water SCHEMBL2557169 | 0.99 | MAPK1 (0.63) | MAPK1NOD2ALDH1A1THRBLGALS8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 122 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160076032-A1 | COMPOSITIONS AND METHODS | ISIS PHARMACEUTICALS, INC. (US) | 2016-03-17 | — | — | US | claimed |
| US-12030910-B2 | Compounds and methods for the modulation of proteins | IONIS PHARMACEUTICALS, INC. (US) | 2024-07-09 | — | — | US | disclosed |
| US-20240093201-A1 | COMPOSITIONS AND METHODS FOR ENHANCED INTESTINAL ABSORPTION OF CONJUGATED OLIGOMERIC COMPOUNDS | IONIS PHARMACEUTICALS, INC. (US) | 2024-03-21 | — | — | US | disclosed |
| US-20240026364-A1 | COMPOUNDS AND METHODS FOR MODULATING TMPRSS6 EXPRESSION | IONIS PHARMACEUTICALS, INC. (US) | 2024-01-25 | — | — | US | disclosed |
| US-11851655-B2 | Compositions and methods for modulating apolipoprotein (a) expression | IONIS PHARMACEUTICALS, INC. (US) | 2023-12-26 | — | — | US | disclosed |
| US-20230357776-A1 | COMPOSITIONS AND METHODS FOR MODULATING COMPLEMENT FACTOR B EXPRESSION | IONIS PHARMACEUTICALS, INC. (US) | 2023-11-09 | — | — | US | disclosed |
| US-11732265-B2 | Compositions and methods for modulating complement factor B expression | IONIS PHARMACEUTICALS, INC. (US) | 2023-08-22 | — | — | US | disclosed |
| EP-4223315-A2 | METHOD FOR SYNTHESIS OF REACTIVE CONJUGATE CLUSTERS | Ionis Pharmaceuticals, Inc. (US) | 2023-08-09 | — | — | EP | disclosed |
| EP-4219718-A2 | COMPOSITIONS AND METHODS FOR MODULATING COMPLEMENT FACTOR B EXPRESSION | Ionis Pharmaceuticals, Inc. (US) | 2023-08-02 | — | — | EP | disclosed |
| US-20230151365-A1 | COMPOSITIONS AND METHODS FOR MODULATING TTR EXPRESSION | IONIS PHARMACEUTICALS, INC. (US) | 2023-05-18 | — | — | US | disclosed |
| US-20150315594-A1 | COMPOSITIONS AND METHODS FOR MODULATING ANGIOPOIETIN-LIKE 3 EXPRESSION | ISIS PHARMACEUTICALS, INC. (US) | 2015-11-05 | — | — | US | disclosed |
| WO-2015168532-A2 | COMPOSITIONS AND METHODS FOR MODULATING PKK EXPRESSION | ISIS PHARMACEUTICALS, INC. (US) | 2015-11-05 | — | — | WO | disclosed |
| US-9163239-B2 | Compositions and methods for modulating apolipoprotein C-III expression | ISIS PHARMACEUTICALS, INC. (US) | 2015-10-20 | — | — | US | disclosed |
| US-9145558-B2 | Compositions and methods for modulating HBV expression | ISIS PHARMACEUTICALS, INC. (US) | 2015-09-29 | — | — | US | disclosed |
| US-9127276-B2 | Conjugated antisense compounds and their use | ISIS PHARMACEUTICALS, INC. (US) | 2015-09-08 | — | — | US | disclosed |
| US-20150176007-A1 | COMPOSITIONS AND METHODS FOR MODULATING HBV EXPRESSION | ISIS PHARMACEUTICALS, INC. (US) | 2015-06-25 | — | — | US | disclosed |
| US-20150126718-A1 | CONJUGATED ANTISENSE COMPOUNDS AND THEIR USE | ISIS PHARMACEUTICALS, INC. (US) | 2015-05-07 | — | — | US | disclosed |
| US-20150126719-A1 | COMPOSITIONS AND METHODS FOR MODULATING APOLIPOPROTEIN C-III EXPRESSION | ISIS PHARMACEUTICALS, INC. (US) | 2015-05-07 | — | — | US | disclosed |
| US-20150126720-A1 | COMPOSITIONS AND METHODS FOR MODULATING APOLIPOPROTEIN (a) EXPRESSION | ISIS PHARMACEUTICALS, INC. (US) | 2015-05-07 | — | — | US | disclosed |
| US-20140343123-A1 | CONJUGATED ANTISENSE COMPOUNDS AND THEIR USE | ISIS PHARMACEUTICALS, INC. (US) | 2014-11-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230151365-A1 | COMPOSITIONS AND METHODS FOR MODULATING TTR EXPRESSION | TTR, GALNT1, GALNT3 | MAPK1 4758/4885NOD2 1522/4885ALDH1A1 1286/4885 |
| US-20240093201-A1 | COMPOSITIONS AND METHODS FOR ENHANCED INTESTINAL ABSORPTION OF CONJUGATED OLIGOMERIC COMPOUNDS | SI, FABP2, GNE | MAPK1 4769/4885NOD2 147/4885ALDH1A1 2760/4885 |
| US-20160076032-A1 | COMPOSITIONS AND METHODS | FUT6, FUT5, GNE | MAPK1 4637/4885NOD2 143/4885ALDH1A1 1681/4885 |
| US-11851655-B2 | Compositions and methods for modulating apolipoprotein (a) expression | APOB, APOL1, LDLR | MAPK1 3716/4885NOD2 419/4885ALDH1A1 1781/4885 |
| US-20240026364-A1 | COMPOUNDS AND METHODS FOR MODULATING TMPRSS6 EXPRESSION | TMPRSS6, TFRC, TMPRSS11D | MAPK1 4411/4885NOD2 4822/4885ALDH1A1 2289/4885 |
| US-12030910-B2 | Compounds and methods for the modulation of proteins | HNRNPUL2, EFTUD2, UPF1 | MAPK1 2958/4885NOD2 3897/4885ALDH1A1 3914/4885 |
| US-20150176007-A1 | COMPOSITIONS AND METHODS FOR MODULATING HBV EXPRESSION | HAVCR2, HCCS, HDGF | MAPK1 4339/4885NOD2 361/4885ALDH1A1 3686/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.